[go: up one dir, main page]

MXPA04000204A - Estructura cristalizada de colageno tipo iv del hexamero de dominio nc1. - Google Patents

Estructura cristalizada de colageno tipo iv del hexamero de dominio nc1.

Info

Publication number
MXPA04000204A
MXPA04000204A MXPA04000204A MXPA04000204A MXPA04000204A MX PA04000204 A MXPA04000204 A MX PA04000204A MX PA04000204 A MXPA04000204 A MX PA04000204A MX PA04000204 A MXPA04000204 A MX PA04000204A MX PA04000204 A MXPA04000204 A MX PA04000204A
Authority
MX
Mexico
Prior art keywords
hexamer
type
domain
collagen
present
Prior art date
Application number
MXPA04000204A
Other languages
English (en)
Inventor
Sundaramoorthy Minurathinam
Original Assignee
Univ Kansas Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Kansas Medical Center filed Critical Univ Kansas Medical Center
Publication of MXPA04000204A publication Critical patent/MXPA04000204A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)

Abstract

La presente invencion proporciona un hexamero de dominio NC1 cristalizado del colageno Tipo IV y los metodos para hacer el cristal, en donde el hexamero del dominio NC1 se cristaliza de manera que la estructura tri-dimensional del hexamero del dominio NC1 cristalizado puede determinarse a una resolucion de al menos 3 A o mejor. La presente invencion tambien proporciona un metodo para disenar compuestos para inhibir la angiogenesis, el crecimiento tumoral, la metastasis tumoral, la adhesion y/o proliferacion celular endotelial y/o el ensamble de la lamina basal, comprendiendo analizar la estructura tri-dimensional de un hexamero del dominio NC1 del colageno tipo IV cristalizada producido por los metodos de la invencion e identificar y sintetizar los compuestos que se dirigen a las regiones del dominio NC1 que se han identificado por el analisis como siendo importantes para el ensamble del hexamero y el heterotrimero del colageno tipo IV. La presente invencion tambien proporciona polipeptidos novedosos disenados por los metodos de diseno de drogas racionales de la presente invencion, basados en un analisis de la estructura del hexamero NC1 del colageno tipo IV descrito en este documento.
MXPA04000204A 2001-07-27 2002-07-26 Estructura cristalizada de colageno tipo iv del hexamero de dominio nc1. MXPA04000204A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US30852301P 2001-07-27 2001-07-27
US35128901P 2001-10-29 2001-10-29
US36685402P 2002-03-22 2002-03-22
US38536202P 2002-06-03 2002-06-03
PCT/US2002/023763 WO2003012122A2 (en) 2001-07-27 2002-07-26 Crystallized structure of type iv collagen nc1 domain hexamer

Publications (1)

Publication Number Publication Date
MXPA04000204A true MXPA04000204A (es) 2004-03-18

Family

ID=27501950

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04000204A MXPA04000204A (es) 2001-07-27 2002-07-26 Estructura cristalizada de colageno tipo iv del hexamero de dominio nc1.

Country Status (7)

Country Link
US (2) US7122517B2 (es)
EP (1) EP1573025A4 (es)
JP (1) JP2005504037A (es)
AU (1) AU2002329643B2 (es)
CA (1) CA2451942A1 (es)
MX (1) MXPA04000204A (es)
WO (1) WO2003012122A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7387779B2 (en) * 1998-06-17 2008-06-17 Beth Israel Deaconess Medical Center Anti-angiogenic proteins and fragments and methods of use thereof
US7122517B2 (en) 2001-07-27 2006-10-17 Kansas University Medical Center Crystallized structure of type IV collagen NC1 domain hexamer
WO2004067762A2 (en) * 2003-01-27 2004-08-12 University Of Kansas Medical Center Crystallized structure of type iv collagen nc1 domain hexamer
US8158586B2 (en) 2005-04-11 2012-04-17 Pharmagap Inc. Inhibitors of protein kinases and uses thereof
WO2007016763A1 (en) * 2005-08-05 2007-02-15 Pharmagap Inc. Peptides targeted to protein kinase c isoforms and uses thereof
EP2015781A4 (en) 2005-09-12 2009-12-23 Univ Johns Hopkins COMPOSITIONS HAVING ANTIANGIOGENIC ACTIVITY AND USES THEREOF
WO2007145192A1 (ja) 2006-06-12 2007-12-21 Tsukao Yokoyama Ｉｖ型コラーゲン様免疫活性ペプチド
WO2008085828A2 (en) 2007-01-03 2008-07-17 The Johns Hopkins University Peptide modulators of angiogenesis and use thereof
EP2440238A4 (en) * 2009-06-09 2013-01-16 Methods of Treatment
JP5664992B2 (ja) * 2009-08-26 2015-02-04 国立大学法人名古屋大学 細胞特異的ペプチド及びその用途
EP3171889A4 (en) * 2014-07-25 2018-03-14 Goldfinch Biopharma, Inc. Collagen iv replacement
EP3319630A1 (en) 2015-07-09 2018-05-16 Intervacc AB Vaccine against s.suis infection

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5354690A (en) * 1989-07-07 1994-10-11 Karl Tryggvason Immunological methods for the detection of the human type IV collagen α5 chain
US5114840A (en) * 1989-07-07 1992-05-19 Karl Tryggvason Method for determining the nucleotide sequence of a novel α5(IV) chain of human type IV collagen
US6277558B1 (en) * 1990-11-30 2001-08-21 Kansas University Medical Center α-3 chain type IV collagen polynucleotides
US5629327A (en) * 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
US5567609A (en) * 1994-06-30 1996-10-22 University Of Kansas Medical Center Use of isolated domains of type IV collagen to modify cell and tissue interactions
US6440729B1 (en) * 1995-06-30 2002-08-27 University Of Kansas Medical Center Treating angiogenesis-mediated diseases with the α2 monomer of type IV collagen
US6358735B1 (en) * 1995-06-30 2002-03-19 University Of Kansas Medical Center Method for inhibiting angiogenesis and tumors with the isolated NC1 α3 chain monomer of type IV collagen
ES2224627T3 (es) * 1998-03-27 2005-03-01 The University Of Kansas Medical Center El uso de dominios aislados de colageno tipo iv para modificar interacciones celulares y tisulares.
EP1086129A1 (en) * 1998-06-17 2001-03-28 Beth Israel Deaconess Medical Center Anti-angiogenic proteins and methods of use thereof
WO2000059532A1 (en) 1999-04-01 2000-10-12 Biostratum, Inc. The use of domains of type iv collagen t inhibit angiogenesis an tumour growth
AU783662B2 (en) * 2000-01-07 2005-11-24 Beth Israel Deaconess Medical Center Anti-angiogenic proteins and fragments and methods of use thereof
US7122517B2 (en) 2001-07-27 2006-10-17 Kansas University Medical Center Crystallized structure of type IV collagen NC1 domain hexamer
WO2004067762A2 (en) 2003-01-27 2004-08-12 University Of Kansas Medical Center Crystallized structure of type iv collagen nc1 domain hexamer

Also Published As

Publication number Publication date
US20030100510A1 (en) 2003-05-29
WO2003012122A3 (en) 2005-12-29
JP2005504037A (ja) 2005-02-10
US20070042965A1 (en) 2007-02-22
CA2451942A1 (en) 2003-02-13
AU2002329643B2 (en) 2006-11-16
EP1573025A4 (en) 2006-07-19
US7122517B2 (en) 2006-10-17
WO2003012122A2 (en) 2003-02-13
WO2003012122A8 (en) 2004-03-25
EP1573025A2 (en) 2005-09-14

Similar Documents

Publication Publication Date Title
MXPA04000204A (es) Estructura cristalizada de colageno tipo iv del hexamero de dominio nc1.
Castiblanco et al. Identification of proteins from human permanent erupted enamel
Thompson et al. Tyrosine sulfation modulates activity of tick-derived thrombin inhibitors
Van Rooijen et al. Glycosylation sites and site-specific glycosylation in human Tamm-Horsfall glycoprotein
Bengtson et al. Predatorial borings in late Precambrian mineralized exoskeletons
ATE412891T1 (de) Verbessertes toxizität-screening verfahren
ATE279203T1 (de) Verwendung von substrat-subtraktionsbibliotheken zur unterscheidung von enzymspezifitäten
DE60224291D1 (de) System zur antikörperexpression und- synthese
ATE425277T1 (de) Verfahren zur herstellung eines sputtertargets und sputtertarget
ATE336578T1 (de) Nukleinsäurebindungsproteine
DE69826465D1 (de) Verfahren zur in vitro evolution von proteinfunktionen
EP1371980A3 (en) Assay chamber
GB9821393D0 (en) Protein profiling 2
IL139163A (en) Method of predicting the ability of compounds to modulate the biological activity of receptors
Eyre et al. Maturation of collagen ketoimine cross-links by an alternative mechanism to pyridinoline formation in cartilage
Lang et al. An endoglycosidase-assisted LC-MS/MS-based strategy for the analysis of site-specific core-fucosylation of low-concentrated glycoproteins in human serum using prostate-specific antigen (PSA) as example
Coradin et al. Monitoring proteolytic processing events by quantitative mass spectrometry
Fodor et al. Rearrangement of terminal amino acid residues in peptides by protease-catalyzed intramolecular transpeptidation
Goldman et al. Monitoring proteolysis of recombinant human interferon-γ during batch culture of Chinese hamster ovary cells
EP1736781A4 (en) EFFECTIVE METHOD FOR FUNCTIONAL ANALYSIS AND SCREENING OF PROTEIN USING A FLUORESCENT MADE WITH A CELL-FREE PROTEIN SYNTHESIS SYSTEM
WO2004067762A3 (en) Crystallized structure of type iv collagen nc1 domain hexamer
Yoshimura et al. Elucidation of the sugar recognition ability of the lectin domain of UDP-GalNAc: polypeptide N-acetylgalactosaminyltransferase 3 by using unnatural glycopeptide substrates
Lin et al. Terminal disialylated multiantennary complex-type N-glycans carried on acutobin define the glycosylation characteristics of the Deinagkistrodon acutus venom
ATE314396T1 (de) G-csf-rezeptoragonist-antikörper und methode zu ihrer isolierung mittels durchmusterung
EA199700310A1 (ru) Биологический способ получения соединений дипептидной природы

Legal Events

Date Code Title Description
FG Grant or registration